Our main developments

Opti3D : Ready-to-use kits of artificial tumors® (96 to 384-well microplate) developed from agressive cancer types

OptiPASS : Synthetic culture media adapted to each cancer type

Patent LightSpot : Fluorescent probes to quantify cell resistance following treatment in microtissues or artificial tumors

For all the products, we propose a complete technical and human support in your facilities (Europe)

Learn more

Our main services

CUSTOMIZED MEDIUM DEVELOPMENT

Formulation of new cell culture medium adapted according to requests (OptiPASS customization)

CUSTOMIZED SCREENING

Screening of various molecules to test their impact on 3D cell models

CUSTOMIZED 3D CELL CULTURE MODELS

Development of new 3D cell models of interest

Our future developments

Other 3D cell culture models: mesenchymal stem cells, pancreatic B islets & myocardial tissue

LightSpot® fluorescent probes for the detection and prediction of tumoral resistance to treatment

qodef-fullwidth-slider

A strong academic / industrial partnership

In a public / private partnership context, the Resistance group of team IMoST from Clermont Auvergne University (INSERM 1240), BIOPASS and BIOMARQUEURS companies designed the BIORCELL3D features. Together, they work on the development of biotechnology preclinical tools, useful for treatment optimization and diagnosis.

5 partners with complementary skills

IMoST – Joint Research Unit INSERM / Clermont University n°1240

BIOPASS

BIOMARQUEURS

Regional Anticancer Center Jean Perrin

Carbogen AMCIS

OptiPASS® : Complete Serum-Free cell culture medium

Adapted to 2D cell cultures of various cancer cell types. 

Adapted to improve and standardize artificial tumors®  reproducibility, conservation and growth.

See product